Validated T-47D Xenograft Model:
Subcutaneous And Orthotopic Xenograft Tumor Model

By Altogen Labs, 11200 Menchaca Road, Suite 203, Austin, TX 78748
Phone: (512) 433-6177 | Email: info@altogenlabs.com

Modeling Breast Cancer: The Role of Xenografts in Drug Development

Breast cancer is a highly prevalent malignancy with diverse subtypes requiring targeted treatments. Xenograft models are essential preclinical tools for studying tumor growth, metastasis, and drug response *in vivo*. Cell line-derived xenografts (CDXs), generated from established breast cancer cell lines, provide a reproducible and cost-effective platform for drug screening, while patient-derived xenografts (PDXs) better preserve tumor heterogeneity and clinical relevance. Subcutaneous xenografts allow for easy monitoring, whereas orthotopic models more accurately mimic the tumor microenvironment. Integrating xenograft studies with molecular profiling enhances our understanding of breast cancer progression and therapy resistance. As CDX and PDX models continue to evolve, they remain vital for bridging the gap between *in vitro* studies and clinical applications, driving advancements in targeted breast cancer treatments.

T-47D Cell Line

The T-47D cell line is a hypotriploid epithelial cell line derived from a pleural effusion of a 54-year-old female patient with infiltrating ductal carcinoma of the breast. These cells exhibit characteristics typical of luminal A breast cancer, including estrogen receptor positivity (ER+), progesterone receptor positivity (PR+), and a lack of HER2 overexpression, making them a valuable model for studying hormone receptor-mediated breast cancer progression and treatment. T-47D cells have a relatively low metastatic potential compared to other breast cancer cell lines and are widely used in research focused on endocrine therapy resistance, hormone signaling, and tumorigenesis. Due to their well-characterized receptor expression, they serve as an ideal platform for evaluating selective estrogen receptor modulators (SERMs) and other targeted therapies. Additionally, these cells are a suitable transfection host, allowing for genetic manipulation and molecular studies related to breast cancer pathophysiology. T-47D cells exhibit anchorage-dependent growth and form adherent monolayers *in vitro*, which facilitates their use in drug screening assays and mechanistic studies.



Figure 1. Tumor Histology. H&E stained section of a subcutaneously-implanted T-47D tumor (Altogen Labs).

Altogen Labs Validated T-47D Xenograft Model

The *in vivo* study design for T-47D cells at Altogen Labs begins with maintaining the cells in an exponential growth phase before collection via trypsinization. Cell viability and counts are assessed, and the suspension is diluted to the appropriate working injection volume. NOD/SCID mice (10-12 weeks old) receive a subcutaneous injection in the hind leg containing one million T-47D cells mixed with Matrigel (100-200 µL total volume). Tumor formation is closely monitored, and once tumors reach an average size of 75-150 mm³, animals are randomized into study groups. The compound of interest is administered according to the designated dosing schedule, and tumor growth is measured daily using digital calipers, with body weights recorded two to three times per week. At the study's conclusion, necropsies are performed, and all tumors are resected, weighed, and preserved for further analysis. Tissue samples can be frozen in liquid nitrogen, stored in 10% neutral buffered formalin (NBF) for histology, or processed for genetic analysis.



Figure 2. T-47D breast cancer xenografted in immunocompromised mice, mean values +/- SEM (Altogen Labs).

Animal handling and maintenance at Altogen Labs adhere to IACUC regulations and GLP compliance, ensuring high-quality research standards. Mice are acclimated to the vivarium environment and sorted based on body mass before study initiation. Daily health assessments include tumor monitoring and observation of clinical signs. Comprehensive reports, including experimental methods, results, discussion, raw data, and statistical analysis, are provided to clients. Additional services such as tissue collection, histology, total protein or RNA isolation, and gene expression analysis are available. Xenograft models remain a cornerstone of preclinical oncology research, enabling the evaluation of novel therapeutics against various cancer types. These models facilitate the testing of new drug candidates on tumor growths established through subcutaneous or orthotopic inoculation in immunocompromised mice or rats. Given the complexity of xenograft studies, careful consideration is required when selecting the appropriate animal model, tumorigenic cell line, administration method, and dosing regimen, followed by detailed tumor growth and biomarker analysis, including histology, mRNA, and protein expression profiling.



Figure 3. Tumor weight of T-47D cells in control, buffer only mice and tamoxifen treated mice at end of the study (Altogen Labs).

Preclinical Drug Testing with the Subcutaneous T-47D Breast Cancer Model

The subcutaneous T-47D xenograft model is a widely used *in vivo* system for studying estrogen receptor-positive (ER+) breast cancer and evaluating novel therapeutic agents. In this model, T-47D cells are injected subcutaneously into immunocompromised mice, typically in the hind flank, where tumors develop in a controlled and measurable manner. This approach provides a straightforward and reproducible method for assessing tumor growth kinetics, drug efficacy, and resistance mechanisms. Since T-47D cells depend on estrogen for sustained proliferation, exogenous estrogen supplementation is often required to support tumor establishment and progression. The subcutaneous model enables high-throughput drug screening and facilitates non-invasive tumor volume measurements using digital calipers, allowing for real-time monitoring of therapeutic responses. While lacking the native tumor microenvironment of an orthotopic model, the subcutaneous T-47D xenograft remains a valuable platform for preclinical oncology research due to its simplicity, scalability, and suitability for molecular and histological analyses. This model plays a crucial role in evaluating endocrine therapies, chemotherapy agents, and targeted inhibitors, contributing to the development of improved treatment strategies for ER+ breast cancer.

Orthotopic T-47D Xenograft Model

The orthotopic T-47D xenograft model is a widely utilized preclinical system for studying estrogen receptor-positive (ER+) breast cancer in a biologically relevant microenvironment. In this model, T-47D cells are implanted directly into the mammary fat pad of immunocompromised mice, allowing for tumor growth in a site that closely mimics the natural tumor niche. Unlike subcutaneous xenografts, orthotopic implantation preserves key tumor-stroma interactions, facilitating more accurate assessments of tumor progression, invasion, and response to endocrine therapies. Since T-47D cells require estrogen for optimal growth *in vivo*, estrogen supplementation is typically provided to maintain tumor viability and replicate hormone-driven breast cancer conditions. This model is particularly valuable for evaluating selective estrogen receptor modulators (SERMs), aromatase inhibitors, and combination therapies targeting hormone receptor pathways. Additionally, the orthotopic setting enables the study of metastasis, as tumors can disseminate to secondary sites such as lymph nodes and distant organs. By integrating molecular and histological analyses, the orthotopic T-47D model provides critical insights into tumor biology and therapeutic resistance, supporting the development of more effective breast cancer treatments.

Alternative Chemotherapy: Calycosin Suppresses T-47D Breast Cancer Progression by Targeting BATF/TGFβ1

Calycosin, a natural isoflavone, has shown promising anti-cancer effects by inhibiting the migration and invasion of T-47D breast cancer cells. It achieves this by downregulating BATF, a transcription factor that promotes tumor progression, leading to the suppression of TGFβ1, a key driver of epithelial-mesenchymal transition (EMT). EMT is a crucial process in cancer metastasis, where epithelial cells lose their cell-to-cell adhesion properties and gain migratory and invasive capabilities. In T-47D cells, calycosin treatment resulted in increased expression of E-cadherin (an epithelial marker) and

decreased levels of mesenchymal markers like N-cadherin, Vimentin, and matrix metalloproteinases (MMP-2 and MMP-9). Functional assays confirmed that calycosin significantly reduced tumor cell motility and invasive potential. Additionally, *in vivo* studies demonstrated that calycosin effectively suppressed tumor growth derived from T-47D cells. These findings suggest that calycosin is a promising therapeutic candidate for breast cancer, particularly for targeting metastasis through the BATF/TGFβ1 axis.

Case Study: T-47D Cells Exhibit Reduced Proliferation and Survival in Response to DHW-208

A study conducted by Wang S, *et al.*, published by *Cell Death and Disease* journal investigates the effects of DHW-208, a novel 4-aminoquinazoline derivative, on breast cancer cells, with a particular focus on the T-47D cell line. The research highlights that DHW-208 effectively inhibits the proliferation, migration, and invasion of T-47D cells by targeting the PI3K/AKT/mTOR signaling pathway, a crucial regulator of cancer cell survival. Through *in vitro* experiments, it was demonstrated that DHW-208 induces apoptosis via the mitochondrial pathway and promotes G0/G1 cell cycle arrest in T-47D cells, thereby restricting tumor growth. The compound also exhibited significant anti-tumor effects in an *in vivo* xenograft model using T-47D cells, further confirming its potential as a therapeutic candidate. Western blot analysis revealed that DHW-208 suppresses the phosphorylation of key proteins in the PI3K/AKT/mTOR axis, indicating its role as a dual PI3K/mTOR inhibitor. Furthermore, DHW-208 outperformed BEZ235, a known PI3K/mTOR inhibitor, in reducing tumor growth with lower toxicity. The study provides strong evidence that DHW-208 is a promising drug candidate for breast cancer therapy, particularly for PI3K/AKT/mTOR-driven cancers like T-47D.



Figure 4. T-47D tumor growth was suppressed when treated with DHW (40 mg/kg).

Additional Case Study: RHAMM Inhibits Migration in T-47D Cells via AKT/GSK3β/Snail Signaling

Another study conducted by Wang J, *et al*., published by *The Anatomical Record* journal investigates the role of RHAMM (Receptor for Hyaluronan-Mediated Motility) in regulating cell migration in luminal A breast cancer, focusing on T-47D cells. Contrary to its well-established role in promoting motility in many cancers, RHAMM was found to inhibit migration in T-47D cells. Knockdown of RHAMM in T-47D cells led to an increase in migration and epithelial-to-mesenchymal transition (EMT), marked by reduced E-cadherin expression and elevated Snail levels. Mechanistically, RHAMM deficiency stabilized Snail by enhancing AKT-mediated phosphorylation of GSK3β, leading to decreased Snail degradation and increased pro-migratory signaling. Functional assays, including wound healing and transwell invasion experiments, confirmed that loss of RHAMM significantly enhanced T-47D cell migration. Additionally, *in vivo* models demonstrated that RHAMM knockdown increased lung metastasis of T-47D cells in NOD/SCID mice. These findings reveal a previously unrecognized function of RHAMM as a migration suppressor in luminal A breast cancer and suggest that targeting RHAMM-related pathways could influence metastasis in T-47D-driven tumors.

Chromosomal Instability in T-47D: A Triploid Karyotype with Structural Aberrations

T-47D breast cancer cells exhibit a highly abnormal karyotype characterized by a near-triploid (3n) chromosome number, ranging from 57 to 66 chromosomes. These cells display extensive numerical and structural chromosomal alterations, including deletions, duplications, and translocations. A notable feature of T-47D cells is the frequent loss of chromosomes 1, 2, 4, and 6, as well as the presence of derivative chromosomes resulting from complex rearrangements. Among the most recurrent structural aberrations are translocations involving chromosomes X, 6, 8, 10, and 20, highlighting significant genomic instability. Polyploidy is observed in a subset of T-47D cells, suggesting ongoing chromosomal instability that may contribute to tumor heterogeneity. Comparative cytogenetic analysis reveals that T-47D shares some chromosomal abnormalities with BT474 cells but remains distinct from MCF7, another luminal A breast cancer model. These chromosomal alterations could have implications for gene expression, therapeutic response, and disease progression in ER+/HER2- breast cancer. Understanding the karyotypic complexity of T-47D cells is crucial for their use in breast cancer research and drug development.

The T-47D xenograft model offers a range of experimental options tailored for preclinical breast cancer research. At Altogen Labs, key assessments include Tumor Growth Delay (TGD) and Tumor Growth Inhibition (TGI) studies to evaluate the latency and efficacy of therapeutic interventions. Researchers can customize dosing regimens, including frequency, duration, and administration routes such as intravenous, intratracheal, continuous infusion, intraperitoneal, intratumoral, oral gavage, topical, intramuscular, subcutaneous, intranasal, and advanced micro-injection techniques, including pump-controlled IV injection. Additional studies include tumor immunohistochemistry, blood chemistry analysis, toxicity and survival assessments, and comprehensive health monitoring programs to evaluate systemic effects. To enhance model versatility, alternative cell engraftment sites are available, including orthotopic transplantation, tail vein injection, left ventricular injection for metastasis studies, mammary fat pad implantation, and intraperitoneal injection.



Figure 5. *In vivo* xenograft services at Altogen Labs for T-47D (Altogen Labs).

Further analytical capabilities include detailed histopathological evaluations through gross necropsies, imaging-based assessments such as fluorescence whole-body imaging, and metabolic studies focusing on lipid distribution. A positive control group can be incorporated using cyclophosphamide at a standard dosage of 50 mg/kg administered intramuscularly throughout the study duration to benchmark therapeutic efficacy. These experimental approaches provide a comprehensive framework for evaluating novel oncology therapeutics, enabling researchers to investigate tumor progression, metastatic potential, and treatment response within a controlled preclinical setting.

References:

T-47D Xenograft Model. https://altogenlabs.com/xenograft-models/breast-cancer-xenograft/t-47d-xenograft-model/

Wang J, Li D, Shen W, Sun W, Gao R, Jiang P, Wang L, Liu Y, Chen Y, Zhou W, Wang R, Xiang R, Stupack D, Luo N. RHAMM inhibits cell migration via the AKT/GSK3β/Snail axis in luminal A subtype breast cancer. *Anat Rec* (Hoboken). 2020 Sep;303(9):2344-2356. doi: 10.1002/ar.24321. Epub 2019 Dec 10. PMID: 31769593.

Wang S, Zhang Y, Ren T, Wu Q, Lu H, Qin X, Liu Y, Ding H, Zhao Q. A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway. *Cell Death Dis*. 2020 Jun 30;11(6):491. doi: 10.1038/s41419-020-2690-y. PMID: 32606352; PMCID: PMC7327080.

Zhang Z, Lin M, Wang J, Yang F, Yang P, Liu Y, Chen Z, Zheng Y. Calycosin inhibits breast cancer cell migration and invasion by suppressing EMT via BATF/TGF-β1. *Aging* (Albany NY). 2021 Jun 7;13(12):16009-16023. doi: 10.18632/aging.203093. Epub 2021 Jun 7. PMID: 34096887; PMCID: PMC8266341.

Keywords: T-47D, breast cancer, xenograft, breast, *in vivo*, cancer, preclinical, research, *in vivo* pharmacology, PDX. CDX, orthotopic